Skip to main content

Table 1 Cytokeratin 18 immunostaining in human tumors

From: Diagnostic and prognostic impact of cytokeratin 18 expression in human tumors: a tissue microarray study on 11,952 tumors

  Entity On TMA (n) CK18 immunostaining
Analyzable (n) Negative (%) Weak (%) Moderate (%) Strong (%) Positive (%)
Tumors of the skin Pilomatrixoma 35 28 100.0 0.0 0.0 0.0 0.0
  Basal cell carcinoma 48 42 100.0 0.0 0.0 0.0 0.0
  Benign nevus 29 23 100.0 0.0 0.0 0.0 0.0
  Squamous cell carcinoma of the skin 50 44 93.2 6.8 0.0 0.0 6.8
  Malignant melanoma 48 43 100.0 0.0 0.0 0.0 0.0
  Merkel cell carcinoma 46 43 32.6 16.3 23.3 27.9 67.4
Tumors of the head and neck Squamous cell carcinoma of the larynx 50 43 72.1 25.6 0.0 2.3 27.9
  Oral squamous cell carcinoma (floor of the mouth) 50 43 93.0 7.0 0.0 0.0 7.0
  Pleomorphic adenoma of the parotid gland 50 42 23.8 50.0 19.0 7.1 76.2
  Warthin tumor of the parotid gland 49 47 0.0 40.4 36.2 23.4 100.0
  Basal cell adenoma of the salivary gland 15 15 6.7 60.0 6.7 26.7 93.3
Tumors of the lung, pleura and thymus Adenocarcinoma of the lung 200 176 0.0 29.5 28.4 42.0 100.0
  Squamous cell carcinoma of the lung 77 66 39.4 48.5 7.6 4.5 60.6
  Small cell carcinoma of the lung 20 16 18.8 12.5 50.0 18.8 81.3
  Malignant mesothelioma 48 40 12.5 12.5 15.0 60.0 87.5
  Mesothelioma, other types 28 18 11.1 33.3 16.7 38.9 88.9
  Mesothelioma, epitheloid 39 26 3.8 11.5 34.6 50.0 96.2
Tumors of the female genital tract Squamous cell carcinoma of the vagina 48 20 90.0 5.0 0.0 5.0 10.0
  Squamous cell carcinoma of the vulva 50 33 100.0 0.0 0.0 0.0 0.0
  Squamous cell carcinoma of the cervix 50 35 88.6 2.9 0.0 8.6 11.4
  Adenocarcinoma of the cervix uteri 50 38 0.0 13.2 23.7 63.2 100.0
  Endometrioid endometrial carcinoma 236 212 0.5 14.2 22.2 63.2 99.5
  Endometrial serous carcinoma 82 53 1.9 15.1 34.0 43.4 92.5
  Carcinosarcoma of the uterus 48 38 21.1 26.3 34.2 18.4 78.9
  Endometrial clear cell carcinoma 8 7 0.0 57.1 42.9 0.0 100.0
  Endometrial carcinoma, low differentiated G3 13 12 33.3 33.3 25.0 8.3 66.7
  Endometrial stromal sarcoma 12 10 100.0 0.0 0.0 0.0 0.0
  Endometrioid carcinoma of the ovary 115 86 1.2 4.7 26.7 67.4 98.8
  Serous carcinoma of the ovary 567 495 0.8 13.7 31.9 53.5 99.2
  Mucinous carcinoma of the ovary 97 75 0.0 17.3 18.7 64.0 100.0
  Clear cell carcinoma of the ovary 54 47 8.5 34.0 31.9 25.5 91.5
  Carcinosarcoma of the ovary 47 41 22.0 14.6 24.4 39.0 78.0
  Brenner tumor 9 8 62.5 37.5 0.0 0.0 37.5
Tumors of the breast Invasive breast carcinoma of no special type 1391 1001 3.6 21.8 23.5 50.9 96.2
  Lobular carcinoma of the breast 294 229 0.4 21.0 26.6 52.0 99.6
  Medullary carcinoma of the breast 26 22 59.1 18.2 9.1 13.6 40.9
  Tubular carcinoma of the breast 27 17 0.0 23.5 17.6 58.8 100.0
  Mucinous carcinoma of the breast 58 35 0.0 11.4 37.1 51.4 100.0
  Phyllodes tumor of the breast 50 32 0.0 37.5 21.9 40.6 100.0
Tumors of the digestive system Adenomatous polyp, low-grade dysplasia 50 41 0.0 0.0 0.0 100.0 100.0
  Adenomatous polyp, high-grade dysplasia 50 44 0.0 0.0 2.3 97.7 100.0
  Adenocarcinoma of the colon 1932 1750 2.6 2.3 9.9 85.3 97.4
  Adenocarcinoma of the small intestine 10 5 0.0 0.0 0.0 100.0 100.0
  Gastric adenocarcinoma, diffuse type 226 161 5.6 32.3 28.6 33.5 94.4
  Gastric adenocarcinoma, intestinal type 224 156 7.1 23.7 19.2 50.0 92.9
  Gastric adenocarcinoma, mixed type 62 59 5.1 25.4 22.0 47.5 94.9
  Adenocarcinoma of the esophagus 133 70 1.4 12.9 7.1 78.6 98.6
  Squamous cell carcinoma of the esophagus 124 63 68.3 22.2 0.0 9.5 31.7
  Squamous cell carcinoma of the anal canal 50 33 75.8 15.2 9.1 0.0 24.2
  Cholangiocarcinoma 130 112 1.8 17.0 29.5 51.8 98.2
  Hepatocellular carcinoma 50 49 8.2 28.6 20.4 42.9 91.8
  Ductal adenocarcinoma of the pancreas 612 523 1.0 16.8 25.6 56.6 99.0
  Pancreatic/Ampullary adenocarcinoma 89 76 5.3 6.6 25.0 63.2 94.7
  Acinar cell carcinoma of the pancreas 13 12 0.0 0.0 16.7 83.3 100.0
  Gastrointestinal stromal tumor (GIST) 50 42 97.6 2.4 0.0 0.0 2.4
Tumors of the urinary system Non-invasive papillary urothelial carcinoma, pTa G2 low grade 177 109 41.3 11.9 23.9 22.9 58.7
  Non-invasive papillary urothelial carcinoma, pTa G2 high grade 141 100 36.0 20.0 24.0 20.0 64.0
  Non-invasive papillary urothelial carcinoma, pTa G3 187 144 18.8 27.8 24.3 29.2 81.3
  Urothelial carcinoma, pT2-4 G3 1164 939 39.7 28.1 14.7 17.5 60.3
  Small cell neuroendocrine carcinoma of the bladder 18 18 33.3 33.3 11.1 22.2 66.7
  Sarcomatoid urothelial carcinoma 25 18 66.7 33.3 0.0 0.0 33.3
  Clear cell renal cell carcinoma 858 722 47.5 31.2 14.3 7.1 52.5
  Papillary renal cell carcinoma 255 209 2.4 15.3 15.8 66.0 97.1
  Chromophobe renal cell carcinoma 131 112 0.9 9.8 20.5 68.8 99.1
  Oncocytoma 177 144 1.4 11.8 16.7 69.4 97.9
  Clear cell (tubulo) papillary renal cell carcinoma 21 18 27.8 5.6 16.7 50.0 72.2
Tumors of the male genital organs Adenocarcinoma of the prostate, Gleason 3 + 3 83 82 0.0 1.2 1.2 97.6 100.0
  Adenocarcinoma of the prostate, Gleason 4 + 4 80 73 0.0 4.1 1.4 94.5 100.0
  Adenocarcinoma of the prostate, Gleason 5 + 5 85 81 0.0 3.7 11.1 85.2 100.0
  Adenocarcinoma of the prostate (recurrence) 330 287 6.3 16.0 27.9 49.8 93.7
  Small cell neuroendocrine carcinoma of the prostate 17 16 25.0 18.8 37.5 18.8 75.0
  Seminoma 220 204 97.5 2.5 0.0 0.0 2.5
  Germ cell neoplasia in situ 85 67 64.2 29.9 3.0 3.0 35.8
  Embryonal carcinoma of the testis 50 46 0.0 23.9 19.6 56.5 100.0
  Yolk sack tumor 50 42 0.0 38.1 21.4 40.5 100.0
  Teratoma 50 27 70.4 14.8 0.0 14.8 29.6
Tumors of endocrine organs Adenoma of the thyroid gland 114 109 0.0 5.5 35.8 58.7 100.0
  Papillary thyroid carcinoma 392 381 0.3 1.6 14.7 83.5 99.7
  Follicular thyroid carcinoma 158 150 0.0 2.0 34.0 64.0 100.0
  Medullary thyroid carcinoma 107 98 1.0 6.1 33.7 59.2 99.0
  Anaplastic thyroid carcinoma 45 43 41.9 32.6 14.0 11.6 58.1
  Adrenal cortical adenoma 50 36 91.7 5.6 0.0 2.8 8.3
  Adrenal cortical carcinoma 26 20 70.0 10.0 0.0 20.0 30.0
  Phaeochromocytoma 50 42 100.0 0.0 0.0 0.0 0.0
  Appendix, neuroendocrine tumor (NET) 22 15 0.0 8.3 0.0 91.7 100.0
  Colorectal, neuroendocrine tumor (NET) 10 10 0.0 0.0 10.0 90.0 100.0
  Ileum, neuroendocrine tumor (NET) 49 45 0.0 2.2 2.2 95.6 100.0
  Lung, neuroendocrine tumor (NET) 19 18 0.0 11.8 17.6 70.6 100.0
  Pancreas, neuroendocrine tumor (NET) 102 79 1.3 5.1 31.6 62.0 98.7
  Colorectal, neuroendocrine carcinoma (NEC) 11 9 33.3 22.2 22.2 22.2 66.7
  Gallbladder, neuroendocrine carcinoma (NEC) 4 4 50.0 0.0 25.0 25.0 50.0
  Pancreas, neuroendocrine carcinoma (NEC) 13 7 28.6 28.6 0.0 42.9 71.4
Tumors of haemotopoetic and lymphoid tissues Hodgkin Lymphoma 45 39 100.0 0.0 0.0 0.0 0.0
  Non-Hodgkin Lymphoma 48 41 100.0 0.0 0.0 0.0 0.0
Tumors of soft tissue and bone Tenosynovial giant cell tumor 45 43 100.0 0.0 0.0 0.0 0.0
  Granular cell tumor 53 32 100.0 0.0 0.0 0.0 0.0
  Leiomyoma 50 32 100.0 0.0 0.0 0.0 0.0
  Angiomyolipoma 91 74 98.6 1.4 0.0 0.0 1.4
  Angiosarcoma 73 55 87.3 7.3 3.6 1.8 12.7
  Dermatofibrosarcoma protuberans 21 16 100.0 0.0 0.0 0.0 0.0
  Ganglioneuroma 14 11 100.0 0.0 0.0 0.0 0.0
  Kaposi sarcoma 8 5 100.0 0.0 0.0 0.0 0.0
  Leiomyosarcoma 87 70 100.0 0.0 0.0 0.0 0.0
  Liposarcoma 132 98 100.0 0.0 0.0 0.0 0.0
  Malignant peripheral nerve sheath tumor (MPNST) 13 12 100.0 0.0 0.0 0.0 0.0
  Myofibrosarcoma 26 24 100.0 0.0 0.0 0.0 0.0
  Neurofibroma 117 103 100.0 0.0 0.0 0.0 0.0
  Sarcoma, not otherwise specified (NOS) 75 67 94.0 4.5 1.5 0.0 6.0
  Paraganglioma 41 37 100.0 0.0 0.0 0.0 0.0
  Primitive neuroectodermal tumor (PNET) 23 13 100.0 0.0 0.0 0.0 0.0
  Rhabdomyosarcoma 7 6 100.0 0.0 0.0 0.0 0.0
  Schwannoma 121 93 98.9 0.0 1.1 0.0 1.1
  Synovial sarcoma 12 10 100.0 0.0 0.0 0.0 0.0
  Osteosarcoma 43 29 96.6 3.4 0.0 0.0 3.4
  Chondrosarcoma 39 21 100.0 0.0 0.0 0.0 0.0
\